This article is a correction to:
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
Johannes Sam1
Sara Colombetti1
Tanja Fauti1
Andreas Roller2Marlene Biehl1
Linda Fahrni1
Valeria Nicolini1
Mario Perro1
Tapan Nayak2
Esther Bommer1Anne Schoenle1
Maria Karagianni1Marine Le Clech1Nathalie Steinhoff1
Christian Klein1
Pablo Umaña1*
Marina Bacac1*- 1Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- 2Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
A Corrigendum on
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
By Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P and Bacac M (2020). Front. Oncol. 10:575737. doi: 10.3389/fonc.2020.575737
In the published article, there was an error in affiliations 1 and 2. Instead of “Roche Pharmaceutical Research & Early Development”, it should be “Roche Pharma Research & Early Development”.
In the original article, there was an error in the Conflict of Interest section. Author ownership interests were omitted from the Conflict of Interest.
A correction has been made to the Conflict of Interest section:
The authors declare that this study received funding from F Hoffmann-La Roche Ltd. The funder had the following involvement with the study: study design, generation of the molecules tested in the study, data collection and analysis, decision to publish, and editorial support for the preparation of this manuscript. All authors are employees of F Hoffmann-La Roche Ltd. Authors JS, SC, TF, AR, MBi, LF, TN, AS, MLC, CK, PU, and MBa hold stock/stock options for F Hoffmann-La Roche Ltd and authors JS, SC, TF, VG-N, MP, TN, AS, CK, PU, and MBa hold patents related to the TCB technologies reported in the manuscript.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: solid tumors, immunotherapy, T-cell bispecific antibody, carcinoembryonic antigen T-cell bispecific antibody, programmed death–ligand 1, combination, humanized mice
Citation: Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P and Bacac M (2021) Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Front. Oncol. 11:650149. doi: 10.3389/fonc.2021.650149
Received: 06 January 2021; Accepted: 12 January 2021;
Published: 03 February 2021.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2021 Sam, Colombetti, Fauti, Roller, Biehl, Fahrni, Nicolini, Perro, Nayak, Bommer, Schoenle, Karagianni, Le Clech, Steinhoff, Klein, Umaña and Bacac. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marina Bacac, marina.bacac@roche.com; Pablo Umaña, pablo.umana@roche.com